Welcome to UChicago PCCM Research!
Research defining the mechanisms, diagnosis, and treatment of lung disease and critical illness is a central mission of our group. This research is conducted in our clinical facilities as well as our basic research laboratories. Investigators are actively engaged in studying lung biology and cellular function related to critical illness, using techniques of cell and molecular biology, immunology, and genetics. Large and innovative clinical studies are also in place, with questions related to diagnosis and management of diverse diseases answered by accomplished clinical scientists observing individual patients and patient populations.
The strength of our research enterprise derives from the high degree of collaboration between basic and clinical scientists, and the joining of faculty and research associates with diverse training, expertise, and interests. The PhD, MD, and MD-PhD investigators in our group sustain this multi-faceted and dynamic approach to biomedical research. The essence of this activity is to ask important questions, and to answer them with whatever means are necessary—often employing the means of both clinical and basic science. The flow of ideas and findings is from bedside to bench and back, with each discovery adding to new questions requiring creative approaches to answer them. This exciting atmosphere provides abundant learning opportunities for students at every level of training, and we have successfully incorporated college, medical, and graduate students; post-doctoral scientists; residents; and fellows in our many programs.
News
Best Junior Investigator Award, 2021
Congratulations to Parker Woods, PhD for winning the AJRCMB Best Junior Investigator Award!
for his paper on
Tissue-Resident Alveolar Macrophages Do Not Rely on Glycolysis for LPS-induced Inflammation
“These findings demonstrate that glycolysis is dispensable for macrophage effector function in TR-AM and highlight the importance of macrophage tissue origin (tissue resident vs. recruited) in immunometabolism.”
Mechanosensitive transcription factor KLF2 is down regulated in COVID19 lungs
Hot off the (electronic) press!
Published in The American Journal of Respiratory Cell and Molecular Biology [link]